Policy Implications of Oral Agents

Seminars in Oncology Nursing

Volumn 27, Issue 2, 2011, Pages 161-165

  Spoelstra, Sandra L ^a   Given, Barbara A ^a   Given, Charles W ^a   Grant, Marcia ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Adherence; Antineoplastic; Cancer; Oral agents; Scope of problems

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; HEALTH CARE POLICY; HUMAN; NEOPLASM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; HEALTH POLICY; HUMANS; NEOPLASMS;

EID: 79955011077     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2011.02.008     Document Type: Article

References (11)

1. Weingart S.N., Brown E., Bach P.B., et al. NCCN Task force report: oral chemotherapy. J Natl Compr Canc Netw 2008, 6(suppl 3):S1-S14.
2. Suchanek D. The rise and role of specialty pharmacies. Biotech Healthcare 2005, 10:31-35.
3. DiMatteo M.R., Giordani P.J., Lepper H.S., et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002, 40:794-811.
4. Saver B.G., Doescher M., Jackson E., et al. Seniors with chronic health conditions and prescription drugs: benefits, wealth, and health. Value Health 2004, 7:133-136.
5. Chernew M.E., Shah M.R., Wegh A., et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood) 2008, 27:103-112.
6. Sokol M., McGuigan K., Verrugge R., et al. Impact of medication adherence on hospitalization risk of healthcare costs. Med Care 2005, 43:521-530.
7. Twelves C., Gollins S., Grieve R., et al. A randomized cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006, 17:239-245.
8. Bender B.G. Risk taking, depression, adherence, and symptom control in adolescents and young adults with asthma. Am J Respir Crit Care Med 2006, 173:953-957.
9. MacLeod A., Branch A., Cassidy J., et al. A nurse/pharmacy led capecitabine clinic for colorectal cancer: results of a prospective audit and retrospective survey of patient experiences. Eur J Oncol Nurs 2007, 11:247-254.
10. Given B.A., Given C.W., Spoelstra S. Intervention to improve adherence and symptoms from oral agents: final scientific report December 2010, Oncology Nursing Society Foundation, Pittsburgh, PA.
11. Mayer E.L., Partridge A.H., Harris L.N., et al. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat 2009, 117:615-623.